Literature DB >> 11744011

The inflammatory response in myocardial infarction.

Nikolaos G Frangogiannis1, C Wayne Smith, Mark L Entman.   

Abstract

One of the major therapeutic goals of modern cardiology is to design strategies aimed at minimizing myocardial necrosis and optimizing cardiac repair following myocardial infarction. However, a sound understanding of the biology is necessary before a specific intervention is pursued on a therapeutic basis. This review summarizes our current understanding of the cellular and molecular mechanisms regulating the inflammatory response following myocardial ischemia and reperfusion. Myocardial necrosis induces complement activation and free radical generation, triggering a cytokine cascade initiated by Tumor Necrosis Factor (TNF)-alpha release. If reperfusion of the infarcted area is initiated, it is attended by an intense inflammatory reaction. Interleukin (IL)-8 synthesis and C5a activation have a crucial role in recruiting neutrophils in the ischemic and reperfused myocardium. Neutrophil infiltration is regulated through a complex sequence of molecular steps involving the selectins and the integrins, which mediate leukocyte rolling and adhesion to the endothelium. Marginated neutrophils exert potent cytotoxic effects through the release of proteolytic enzymes and the adhesion with Intercellular Adhesion Molecule (ICAM)-1 expressing cardiomyocytes. Despite this potential injury, substantial evidence suggests that reperfusion enhances cardiac repair improving patient survival; this effect may be in part related to the inflammatory response. Monocyte Chemoattractant Protein (MCP)-1 is also markedly upregulated in the infarcted myocardium inducing recruitment of mononuclear cells in the injured areas. Monocyte-derived macrophages and mast cells may produce cytokines and growth factors necessary for fibroblast proliferation and neovascularization, leading to effective repair and scar formation. At this stage expression of inhibitory cytokines such as IL-10 may have a role in suppressing the acute inflammatory response and in regulating extracellular matrix metabolism. Fibroblasts in the healing scar undergo phenotypic changes expressing smooth muscle cell markers. Our previous review in this journal focused almost exclusively on reduction of the inflammatory injury. The current update is prompted by the potential therapeutic opportunity that the open vessel offers. By promoting more effective tissue repair, it may be possible to reduce the deleterious remodeling, that is the leading cause of heart failure and death. Elucidating the complex interactions and regulatory mechanisms responsible for cardiac repair may allow us to design effective inflammation-related interventions for the treatment of myocardial infarction.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2002        PMID: 11744011     DOI: 10.1016/s0008-6363(01)00434-5

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  576 in total

Review 1.  Monocytes: protagonists of infarct inflammation and repair after myocardial infarction.

Authors:  Matthias Nahrendorf; Mikael J Pittet; Filip K Swirski
Journal:  Circulation       Date:  2010-06-08       Impact factor: 29.690

Review 2.  Is CaMKII a link between inflammation and hypertrophy in heart?

Authors:  Madhu V Singh; Mark E Anderson
Journal:  J Mol Med (Berl)       Date:  2011-01-29       Impact factor: 4.599

3.  Phenotypic and functional alterations on inflammatory peripheral blood cells after acute myocardial infarction.

Authors:  Tiago Carvalheiro; Isabel Velada; Ana Valado; Fernando Mendes; António Martinho; Natália António; Lino Gonçalves; Luís Providência; Maria Luísa Pais; Artur Paiva
Journal:  J Cardiovasc Transl Res       Date:  2012-04-21       Impact factor: 4.132

Review 4.  Cardiac cell therapy: boosting mesenchymal stem cells effects.

Authors:  E Samper; A Diez-Juan; J A Montero; P Sepúlveda
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 5.  Cardiac mast cells: the centrepiece in adverse myocardial remodelling.

Authors:  Scott P Levick; Giselle C Meléndez; Eric Plante; Jennifer L McLarty; Gregory L Brower; Joseph S Janicki
Journal:  Cardiovasc Res       Date:  2010-08-24       Impact factor: 10.787

6.  Peri-infarct zone characterized by cardiac magnetic resonance imaging is directly associated with the inflammatory activity during acute phase myocardial infarction.

Authors:  Jose C Quinaglia e Silva; Otavio Rizzi Coelho-Filho; Joalbo M Andrade; Thiago Quinaglia; Rodrigo G P Modolo; Breno O Almeida; Rob J van der Geest; Michael Jerosch-Herold; Otavio Rizzi Coelho; Andrei C Sposito
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

Review 7.  The cardiac hypoxic niche: emerging role of hypoxic microenvironment in cardiac progenitors.

Authors:  Wataru Kimura; Hesham A Sadek
Journal:  Cardiovasc Diagn Ther       Date:  2012-12

8.  Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion.

Authors:  Christina J Mackins; Seiichiro Kano; Nahid Seyedi; Ulrich Schäfer; Alicia C Reid; Takuji Machida; Randi B Silver; Roberto Levi
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

9.  Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart.

Authors:  DeLisa Fairweather; Sylvia Frisancho-Kiss; Susy A Yusung; Masheka A Barrett; Sarah E Davis; Shannon J L Gatewood; Dolores B Njoku; Noel R Rose
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

10.  Anti-inflammatory effect of B-type natriuretic peptide postconditioning during myocardial ischemia-reperfusion: involvement of PI3K/Akt signaling pathway.

Authors:  Gangying Hu; Xingyue Huang; Kai Zhang; Hong Jiang; Xiaorong Hu
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.